Cited by 818Multiple Sclerosis Research StudiesPeripheral Neuropathies and DisordersPolyomavirus and related diseases

The DOI matches its Crossref record; 96 of the 98 references it cites were found in a registry or an index.

Primary-progressive multiple sclerosis

Miller, David H, Leary, Siobhan M·2007·The Lancet Neurology

Open this paper in CoChat — free account

Abstract

About 10-15% of patients with multiple sclerosis (MS) present with gradually increasing neurological disability, a disorder known as primary-progressive multiple sclerosis (PPMS). Compared with relapse-onset multiple sclerosis, people with PPMS are older at onset and a higher proportion are men. Inflammatory white-matter lesions are less evident but diffuse axonal loss and microglial activation are seen in healthy-looking white matter, in addition to cortical demyelination, and quantitative MRI shows atrophy and intrinsic abnormalities in the grey matter and the white matter. Spinal cord atrophy corresponds to the usual clinical presentation of progressive spastic paraplegia. Although neuroaxonal degeneration seems to underlie PPMS, the pathogenesis and the extent to which immune-mediated mechanisms operate is unclear. MRI of the brain and spinal cord, and examination of the CSF, are important investigations for diagnosis; conventional immunomodulatory therapies, such as interferon beta and glatiramer acetate, are ineffective. Future research should focus on the clarification of the mechanisms of axonal loss, improvements to the design of clinical trials, and the development of effective neuroprotective treatments.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(07)70243-0

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H., Kappos, L., Lublin, F. D., Metz, L. M., McFarland, H. F., O'Connor, P. W., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20703 · Cited by 5,017
Defining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Relapses and Progression of Disability in Multiple Sclerosis
Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432001 · Cited by 1,328
Development of a multiple sclerosis functional composite as a clinical trial outcome measure
Cutter, G. (1999) · Brain · doi:10.1093/brain/122.5.871 · Cited by 1,191
The natural history of multiple sclerosis:a geographically based study
Cottrell, D. A., Kremenchutzky, M., Rice, G. P., Koopman, W. J., Hader, W. J., Baskerville, J., & Ebers, G. C. (1999) · Brain · doi:10.1093/brain/122.4.625 · Cited by 1,169
The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure
Hobart, J. (2001) · Brain · doi:10.1093/brain/124.5.962 · Cited by 1,144
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898

Show all 98 references

Research works printed but not linked: 1

Kita, 2004, A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis, Neurology, 62, A99

Sorted by citations

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H.-P., Hemmer, B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606468 · Cited by 1,905
Multiple sclerosis
Thompson, A. J., Baranzini, S. E., Geurts, J. J. G., Hemmer, B., & Ciccarelli, O. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30481-1 · Cited by 1,979
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial
Hawker, K., O'Connor, P. W., Freedman, M. S., Calabresi, P. A., Antel, J. P., Simon, J. H., Hauser, S. L., Waubant, E. L., Vollmer, T. L., PANITCH, H. S., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21867 · Cited by 951
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Montalbán, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comı, G., Derfuss, T. J., Fazekas, F., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517751049 · Cited by 739
Self-citation
Diagnosis of multiple sclerosis: progress and challenges
Brownlee, W. J., Hardy, T. A., Fazekas, F., & Miller, D. H. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30959-x · Cited by 701
Self-citation
FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulation
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R. R., Lee, C., Noguchi, K., Teo, S. T., Yung, Y. C., Lu, M., Kennedy, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014154108 · Cited by 598
Multiple sclerosis
Nylander, A., & Hafler, D. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58649 · Cited by 495
Will the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S. S., Hobart, J. C., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A. L., & Vollmer, T. L. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 480
Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration
Sankowski, R., Mader, S., & ValdÃ©s-Ferrer, S. I. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00028 · Cited by 351
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 398
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 349
Treatment of multiple sclerosis — success from bench to bedside
Tintoré, M., Vidal‐Jordana, Á., & Sastre‐Garriga, J. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 357
Demyelination versus remyelination in progressive multiple sclerosis
Bramow, S., Frischer, J. M., Lassmann, H., Koch‐Henriksen, N., Lucchinetti, C. F., Sørensen, P. S., & Laursen, H. B. (2010) · Brain · doi:10.1093/brain/awq250 · Cited by 320
Classification, diagnosis, and differential diagnosis of multiple sclerosis
Sand, I. K. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000206 · Cited by 359
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
Groves, A., Kihara, Y., & Chun, J. J. M. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.02.011 · Cited by 318
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function
Ontaneda, D., Thompson, A. J., Fox, R. J., & Cohen, J. A. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31320-4 · Cited by 298
MR Imaging of Multiple Sclerosis
Filippi, M., & Rocca, M. A. (2011) · Radiology · doi:10.1148/radiol.11101362 · Cited by 280
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
Quintana, F. J., Farez, M., Viglietta, V., Iglesias, A. H., Merbl, Y., Izquierdo, G., Lucas, M., Basso, A. S., Khoury, S. J., Lucchinetti, C. F., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806310105 · Cited by 243
Introduction to Healthcare for Spanish-speaking Interpreters and Translators
Crezee, I. H. M., Mikkelson, H. M., & Monzon-Storey, L. (2015) · John Benjamins Publishing Company eBooks · doi:10.1075/z.193 · Cited by 226
Multiple sclerosis, a treatable disease
Doshi, A., & Chataway, J. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-6-s53 · Cited by 251
ECTRIMS / EAN guideline on the pharmacological treatment of people with multiple sclerosis
Montalbán, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comı, G., Derfuss, T. J., Fazekas, F., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13536 · Cited by 233
Self-citation
Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS
Ribbons, K. A., McElduff, P., Boz, C., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Grand’Maison, F., Hupperts, R., Grammond, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122686 · Cited by 190
The natural history of primary progressive multiple sclerosis
Koch, M. W., Kingwell, E., Rieckmann, P., & Tremlett, H. L. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c5b47f · Cited by 192
Multiple sclerosis and the role of immune cells
Høglund, R. A. (2014) · World Journal of Experimental Medicine · doi:10.5493/wjem.v4.i3.27 · Cited by 168
Promoting remyelination in multiple sclerosis
Cunniffe, N. G., & Coles, A. J. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09421-x · Cited by 172
Initiation and Progression of Axonopathy in Experimental Autoimmune Encephalomyelitis
Soulika, A. M., Lee, E., McCauley, E., Miers, L. A., Bannerman, P. G. C., & Pleasure, D. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3794-09.2009 · Cited by 161
Neuro-immune crosstalk in CNS diseases
Kerschensteiner, M., Meinl, E., & Hohlfeld, R. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.09.009 · Cited by 162
Multiple sclerosis, a treatable disease
Doshi, A., & Chataway, J. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-6-530 · Cited by 159
Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients
Lukas, C., Sombekke, M. H., Bellenberg, B., Hahn, H. K., Popescu, V., Bendfeldt, K., Radue, E. W., Gass, A., Borgwardt, S., Kappos, L., et al. (2013) · Radiology · doi:10.1148/radiol.13122566 · Cited by 156
Implications of Gut Microbiota in Neurodegenerative Diseases
Zhang, H., Chen, Y., Wang, Z., Xie, G., Liu, M., Yuan, B., Chai, H., Wang, W., & Cheng, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.785644 · Cited by 161
Characterization of relapsing–remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice
Berard, J. L., Wolak, K., Fournier, S., & David, S. (2010) · Glia · doi:10.1002/glia.20935 · Cited by 147
Rehabilitation interventions in multiple sclerosis: an overview
Beer, S. M., Khan, F., & Kesselring, J. (2012) · Journal of Neurology · doi:10.1007/s00415-012-6577-4 · Cited by 155
Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics
Kamma, E., Lasisi, W. O., Libner, C. D., Ng, H. S., & Plemel, J. R. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02408-y · Cited by 157
Assessment and impact of cognitive impairment in multiple sclerosis: An overview
Macías Islas, M. Á., & Ciampi, E. (2019) · Biomedicines · doi:10.3390/biomedicines7010022 · Cited by 144
Introduction to Healthcare for Interpreters and Translators
Crezee, I. H. M. (2013) · John Benjamins Publishing Company eBooks · doi:10.1075/z.181 · Cited by 141
Introduction to Healthcare for Chinese-speaking Interpreters and Translators
Crezee, I. H. M., & Ng, E. N. S. (2016) · John Benjamins Publishing Company eBooks · doi:10.1075/z.202 · Cited by 137
Myelin water imaging reflects clinical variability in multiple sclerosis
Kolind, S., Matthews, L., Johansen‐Berg, H., Leite, M. I., Williams, S., Deoni, S., & Palace, J. A. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.070 · Cited by 131
Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases
Han, S., Lin, Y. C., Wu, T., Salgado, A. D., Mexhitaj, I., Wuest, S. C., Romm, E., Ohayon, J. M., Goldbach‐Mansky, R. T., Vanderver, A. L., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302884 · Cited by 125
Long Noncoding RNAs and Circular RNAs in Autoimmune Diseases
Lodde, V., Murgia, G., Simula, E. R., Steri, M., Floris, M., & Idda, M. L. (2020) · Biomolecules · doi:10.3390/biom10071044 · Cited by 131
Magnetic resonance monitoring of lesion evolution in multiple sclerosis
Rovira, À., Auger, C., & Alonso, J. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285613484079 · Cited by 126
Preclinical disease activity in multiple sclerosis: A prospective study of cognitive performance prior to first symptom
Cortese, M., Riise, T., Bjørnevik, K., Bhan, A., Farbu, E., Grytten, N., Hogenesch, I., Midgard, R., Simonsen, C. S., Telstad, W., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24769 · Cited by 132
Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review
McKay, K. A., Jahanfar, S., Duggan, T., Tkachuk, S., & Tremlett, H. L. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.03.020 · Cited by 121
Neurodegeneration in autoimmune CNS inflammation
Herz, J., Zipp, F., & Siffrin, V. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.11.019 · Cited by 122
Riboflavin in Neurological Diseases: A Narrative Review
Plantone, D., Pardini, M., & Rinaldi, G. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01038-1 · Cited by 115
Multiple sclerosis: New insights and trends
Koriem, K. M. M. (2016) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/j.apjtb.2016.03.009 · Cited by 112
Temperature sensitivity in multiple sclerosis: An overview of its impact on sensory and cognitive symptoms
Christogianni, A., Bibb, R., Davis, S. L., Jay, O., Barnett, M. H., Evangelou, N., & Filingeri, D. (2018) · Temperature · doi:10.1080/23328940.2018.1475831 · Cited by 110
Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases
Wildner, P., Stasiołek, M., & Matysiak, M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.101452 · Cited by 119
A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
Montalbán, X., Sastre‐Garriga, J., Tintoré, M., Brieva, L., Aymerich, F., Río, J., Porcel, J., Borrás, C., Nos, C., & Rovira, À. (2009) · Multiple Sclerosis Journal · doi:10.1177/1352458509106937 · Cited by 109
Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis
Mirmosayyeb, O., Brand, S., Barzegar, M., Afshari-Safavi, A., Nehzat, N., Shaygannejad, V., & Bahmani, D. S. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051326 · Cited by 116
Grey matter damage in multiple sclerosis
Klaver, R., de Vries, H. E., Schenk, G. J., & Geurts, J. J. G. (2013) · Prion · doi:10.4161/pri.23499 · Cited by 114
Predicting progression in primary progressive multiple sclerosis: A 10‐year multicenter study
Khaleeli, Z., Ciccarelli, O., Manfredonia, F., Barkhof, F., Brochet, B., Cercignani, M., Dousset, V., Filippi, M., Montalbán, X., Polman, C. H., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21375 · Cited by 111
Self-citation
Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis
Manrique‐Hoyos, N., Jürgens, T., Grønborg, M., Kreutzfeldt, M., Schedensack, M., Kuhlmann, T., Schrick, C., Brück, W., Urlaub, H., Simons, M., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22681 · Cited by 107
Microbiota–gut–brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets
Chen, C., Wang, G., Li, D., & Zhang, F. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00307-1 · Cited by 133
Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature
Jeong, A., Oleske, D. M., & Holman, J. (2019) · Journal of Child Neurology · doi:10.1177/0883073819845827 · Cited by 107
Behavioural phenotypes in the cuprizone model of central nervous system demyelination
Sen, M. K., Mahns, D. A., Coorssen, J. R., & Shortland, P. J. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.08.008 · Cited by 101
Update on Inflammation, Neurodegeneration, and Immunoregulation in Multiple Sclerosis
Bennett, J. L., & Stüve, O. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181880359 · Cited by 92
New approaches in the management of multiple sclerosis
Allington, D. R. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s9331 · Cited by 92
Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability
Daams, M., Weiler, F., Steenwijk, M. D., Hahn, H. K., Geurts, J. J. G., Vrenken, H., van Schijndel, R. A., Balk, L. J., Tewarie, P. K. B., Tillema, J., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514533399 · Cited by 89
Introduction to Healthcare for Japanese-speaking Interpreters and Translators
Crezee, I. H. M., & Asano, T. (2016) · John Benjamins Publishing Company eBooks · doi:10.1075/z.205 · Cited by 88
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis
Isobe, N., Keshavan, A., Gourraud, P., Zhu, A. H., Datta, E., Schlaeger, R., Caillier, S. J., Santaniello, A., Lizée, A., Himmelstein, D. S., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0980 · Cited by 96
HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter
Melief, J., de Wit, S. J., van Eden, C. G., Teunissen, C. E., Hamann, J., Uitdehaag, B. M. J., Swaab, D. F., & Huitinga, I. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1140-7 · Cited by 89
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide–enhanced MR Imaging
Tourdias, T., Roggerone, S., Filippi, M., Kanagaki, M., Rovaris, M., Miller, D. H., Petry, K. G., Brochet, B., Pruvo, J.-P., Radüe, E.-W., et al. (2012) · Radiology · doi:10.1148/radiol.12111416 · Cited by 85
Self-citation
Comparative gene expression analysis in mouse models for multiple sclerosis, Alzheimer's disease and stroke for identifying commonly regulated and disease-specific gene changes
Tseveleki, V., Rubio, R., Vamvakas, S. M., White, J., Taoufik, E., Petit, E., Quackenbush, J. F., & Probert, L. (2010) · Genomics · doi:10.1016/j.ygeno.2010.04.004 · Cited by 86
Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
Gibiansky, E., Petry, C., Mercier, F., Guenther, A., Herman, A. E., Kappos, L., Hauser, S. L., Yamamoto, Y., Wang, Q., Model, F., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14658 · Cited by 87
Clinical, MRI, and CSF Markers of Disability Progression in Multiple Sclerosis
Gajofatto, A., Calabrese, M., Benedetti, M. D., & Monaco, S. (2013) · Disease Markers · doi:10.1155/2013/484959 · Cited by 83
Cortical remyelination is heterogeneous in multiple sclerosis
Strijbis, E. M. M., Kooi, E.-J., van der Valk, P., & Geurts, J. J. G. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx023 · Cited by 82
Multiple Sclerosis
Vidal‐Jordana, Á., & Montalbán, X. (2017) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2016.12.001 · Cited by 82
The good and the bad of neuroinflammation in multiple sclerosis
Naegele, M., & Martinꝉ, R. (2014) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52001-2.00003-0 · Cited by 85
Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion
Keegan, B. M., Kaufmann, T. J., Weinshenker, B. G., Kantarci, O. H., Schmalstieg, W. F., Paz Soldan, M. M., & Flanagan, E. P. (2016) · Neurology · doi:10.1212/wnl.0000000000003235 · Cited by 80
Meditation as an adjunct to the management of multiple sclerosis.
Levin, A. B., Hadgkiss, E. J., Weiland, T. J., & Jelinek, G. A. (2014) · Neurology Research International · doi:10.1155/2014/704691 · Cited by 77
Interferon Beta for Primary Progressive Multiple Sclerosis
Rojas, J. I., Romano, M., Ciapponi, A., Patrucco, L., & Cristiano, E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006643.pub3 · Cited by 74
Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
Titus, H. E., Chen, Y., Podojil, J. R., Robinson, A. P., Balabanov, R. D., Popko, B., & Miller, S. D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.599717 · Cited by 88
Pediatric multiple sclerosis – current status of epidemiology, diagnosis and treatment
Brola, W., & Steinborn, B. (2020) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2020.0069 · Cited by 76
An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis
Dighriri, I. M., Aldalbahi, A. A., Albeladi, F. I., Tahiri, A. A., Kinani, E. M., Almohsen, R. A., Alamoudi, N. H., Alanazi, A. I., Alkhamshi, S. J., Althomali, N. A., et al. (2023) · Cureus · doi:10.7759/cureus.33242 · Cited by 93
Vitamin D in Neurological Diseases
Plantone, D., Primiano, G., Manco, C., Locci, S., Servidei, S., & Stefano, N. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010087 · Cited by 81
Sexual dimorphism in the white matter of rodents
Cerghet, M., Skoff, R. P., Swamydas, M., & Bessert, D. A. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.06.039 · Cited by 70
Thalamic Damage Predicts the Evolution of Primary-Progressive Multiple Sclerosis at 5 Years
Mesaroš, Š., Rocca, M. A., Pagani, E., Sormani, M. P., Petrolini, M., Comı, G., & Filippi, M. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2430 · Cited by 70
Imaging outcome measures for progressive multiple sclerosis trials
Moccia, M., Stefano, N. D., & Barkhof, F. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517729456 · Cited by 71
Connecting Neuroinflammation and Neurodegeneration in Multiple Sclerosis: Are Oligodendrocyte Precursor Cells a Nexus of Disease?
Psenicka, M. W., Smith, B. C., Tinkey, R. A., & Williams, J. L. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.654284 · Cited by 73
Effects of Natalizumab Treatment on the Cerebrospinal Fluid Proteome of Multiple Sclerosis Patients
Stoop, M. P., Singh, V. P., Stingl, C., Martinꝉ, R., Khademi, M., Olsson, T. P., Hintzen, R. Q., & Luider, T. M. (2013) · Journal of Proteome Research · doi:10.1021/pr3012107 · Cited by 67
Disease-Modifying Agents for Multiple Sclerosis
Menge, T., Weber, M. S., Hemmer, B., Kieseier, B. C., von Büdingen, H. ‐., Warnke, C., Zamvil, S. S., Boster, A. L., Khan, O., Hartung, H. P., et al. (2008) · Drugs · doi:10.2165/0003495-200868170-00004 · Cited by 66
Proteomics Comparison of Cerebrospinal Fluid of Relapsing Remitting and Primary Progressive Multiple Sclerosis
Stoop, M. P., Singh, V. P., Dekker, L. J. M., Titulaer, M. K., Stingl, C., Burgers, P. C., Smitt, P. A. E. S., Hintzen, R. Q., & Luider, T. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012442 · Cited by 66
Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis
Villar, L. M., Casanova, B., Ouamara, N., Comabella, M., Jalili, F., Leppert, D., de Andrés, C., Izquierdo, G., Arroyo, R., Avşar, T., et al. (2014) · Annals of Neurology · doi:10.1002/ana.24190 · Cited by 65
Sex Differences in Neurodegeneration: The Role of the Immune System in Humans
Lopez-Lee, C., Kodama, L., & Gan, L. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.002 · Cited by 69
Depressive Symptoms Correlate with Disability and Disease Course in Multiple Sclerosis Patients: An Italian Multi-Center Study Using the Beck Depression Inventory
Solaro, C. M., Trabucco, E., Signori, A., Martinelli, V., Radaelli, M., Centonze, D., Rossi, S., Grasso, M. G., Clemenzi, A., Bonavita, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160261 · Cited by 64
Diagnosis and Differential Diagnosis of Multiple Sclerosis
Sand, I. K., & LUBLIN, F. D. (2013) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000433290.15468.21 · Cited by 64
Current Advances in Pediatric Onset Multiple Sclerosis
Fisher, K. S., Cuascut, F. X., Rivera, V. M., & Hutton, G. J. (2020) · Biomedicines · doi:10.3390/biomedicines8040071 · Cited by 65
Melatonin treatment improves primary progressive multiple sclerosis: a case report
González, A. L., Álvarez‐Sánchez, N., Lardone, P. J., Cruz‐Chamorro, I., Martínez‐López, A., Guerrero, J. M., Reiter, R. J., & Carrillo‐Vico, A. (2014) · Journal of Pineal Research · doi:10.1111/jpi.12203 · Cited by 62
Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts
Kingwell, E., Leung, A. L., Roger, E., Duquette, P., Rieckmann, P., & Tremlett, H. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.02.007 · Cited by 60
Pharmacokinetic evaluation of idebenone
Becker, C., Bray, K. M., & Drewe, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.530656 · Cited by 59
Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis
Weisfeld‐Adams, J. D., Sand, I. K., Honce, J. M., & LUBLIN, F. D. (2015) · Brain · doi:10.1093/brain/awu397 · Cited by 59
Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis
Lommers, É., Simon, J., Reuter, G., Delrue, G., Dive, D., Degueldre, C., Balteau, E., Phillips, C. L. M., & Maquet, P. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101879 · Cited by 66
Examining trait mindfulness, emotion dysregulation, and quality of life in multiple sclerosis.
Schirda, B., Nicholas, J. A., & Prakash, R. S. (2015) · Health Psychology · doi:10.1037/hea0000215 · Cited by 58
Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis
Xiao, J., Yang, R., Biswas, S., Zhu, Y., Qin, X., Zhang, M., Zhai, L., Luo, Y., He, X., Mao, C., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0566-7 · Cited by 60
CNS Inflammatory Demyelinating Disorders: MS, NMOSD and MOG Antibody Associated Disease
Rosenthal, J. F., Hoffman, B. M., & Tyor, W. R. (2019) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001126 · Cited by 58
Retinal nerve fiber layer thickness in subgroups of multiple sclerosis, measured by optical coherence tomography and scanning laser polarimetry
Siepman, T. A. M., Bettink‐Remeijer, M. W., & Hintzen, R. Q. (2010) · Journal of Neurology · doi:10.1007/s00415-010-5589-1 · Cited by 57
Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity.
Szalardy, L., Zádori, D., Simu, M., Bencsik, K., Vécsei, L., & Klivényi, P. (2013) · Journal of Neurological Sciences · doi:10.1016/j.jns.2013.04.024 · Cited by 56

Authors: Miller, D. H., & Leary, S. M.
Affiliations: UCL Queen Square Institute of Neurology (GB)
University College Hospital (GB)
ORCID: Leary, Siobhan M
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2007-10
Volume: 6
Issue: 10
Pages: 903-912
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(07)70243-0
OpenAlex: W1990040006
Cited by: 818
References: 98
Citations by year: 2026: 18 · 2025: 23 · 2024: 30 · 2023: 32 · 2022: 74 · 2021: 74 · 2020: 29 · 2019: 26 · 2018: 32 · 2017: 33 · 2016: 161 · 2015: 66 · 2014: 33 · 2013: 71 · 2012: 19
FWCI: 2.78
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Multiple Sclerosis Society
Topics: Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
Keywords: primary progressive multiple sclerosis, axonal loss, neuroaxonal degeneration, microglial activation, cortical demyelination, spinal cord atrophy, quantitative MRI, cerebrospinal fluid biomarkers, interferon-beta, glatiramer acetate, neuroprotection, pathogenesis
MeSH terms: Brain, Diagnosis, Differential, Humans, Magnetic Resonance Imaging, Multiple Sclerosis, Chronic Progressive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Primary-progressive multiple sclerosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks